ketanserin has been researched along with Parkinson Disease in 7 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The binding of the selective 5-HT2 antagonist [3H]ketanserin has been investigated in the temporal cortex of patients with Alzheimer's disease (SDAT), Parkinson's disease (PD), senile dementia of Lewy body type (SDLT) and neuropathologically normal subjects (control)." | 3.68 | Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. ( Cheng, AV; Edwardson, JA; Ferrier, IN; Jabeen, S; McKeith, IG; Morris, CM; Perry, EK; Perry, RH; Sahgal, A, 1991) |
| "Parkinson's disease is a neurodegenerative disorder associated with progressive loss of dopaminergic cells in the substantia nigra." | 1.33 | Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. ( Cho, Y; Choi, HJ; Hwang, O; Lee, SY, 2005) |
| "In rodent models of Parkinson's disease (PD) blockade of these receptors increases locomotion and enhances the actions of dopamine (DA) replacement therapy." | 1.33 | Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study. ( Biedka, I; Brus, R; Drosik, M; Kostrzewa, RM; Nowak, P; Szczerbak, G, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrzejewski, K | 1 |
| Kaczyńska, K | 1 |
| Zaremba, M | 1 |
| Choi, HJ | 1 |
| Lee, SY | 1 |
| Cho, Y | 1 |
| Hwang, O | 1 |
| Nowak, P | 1 |
| Szczerbak, G | 1 |
| Biedka, I | 1 |
| Drosik, M | 1 |
| Kostrzewa, RM | 1 |
| Brus, R | 1 |
| Asanuma, M | 1 |
| Miyazaki, I | 1 |
| Diaz-Corrales, FJ | 1 |
| Miyoshi, K | 1 |
| Ogawa, N | 1 |
| Murata, M | 1 |
| Chen, CP | 1 |
| Alder, JT | 1 |
| Bray, L | 1 |
| Kingsbury, AE | 1 |
| Francis, PT | 1 |
| Foster, OJ | 1 |
| Cheng, AV | 1 |
| Ferrier, IN | 1 |
| Morris, CM | 1 |
| Jabeen, S | 1 |
| Sahgal, A | 1 |
| McKeith, IG | 1 |
| Edwardson, JA | 1 |
| Perry, RH | 1 |
| Perry, EK | 1 |
| Maloteaux, JM | 1 |
| Laterre, EC | 1 |
| Laduron, PM | 1 |
| Javoy-Agid, F | 1 |
| Agid, Y | 1 |
7 other studies available for ketanserin and Parkinson Disease
| Article | Year |
|---|---|
Serotonergic system in hypoxic ventilatory response in unilateral rat model of Parkinson's disease.
Topics: Amphetamines; Animals; Brain Stem; Corpus Striatum; Hypoxia; Ketanserin; Male; Organ Specificity; Ox | 2017 |
Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Benzoquinones; Biopterins; Cell Death; Cell | 2005 |
Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study.
Topics: Amphetamine; Animals; Animals, Newborn; Disease Models, Animal; Dopamine; Ketanserin; Male; Microdia | 2006 |
Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation.
Topics: alpha-Synuclein; Animals; Antioxidants; Biopterins; Cell-Free System; Cells, Cultured; Cytosol; Dopa | 2008 |
Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Humans; Ketanserin; Kinetics; Neocortex; Parkinson Disease; | 1998 |
Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Hallucinations; Humans; Ketanserin; Lewy Bodie | 1991 |
Decrease of serotonin-S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy.
Topics: Aged; Aged, 80 and over; Dementia; Humans; Ketanserin; Middle Aged; Parkinson Disease; Receptors, Se | 1988 |